Success Metrics

Clinical Success Rate
83.3%

Based on 5 completed trials

Completion Rate
83%(5/6)
Active Trials
4(36%)
Results Posted
120%(6 trials)
Terminated
1(9%)

Phase Distribution

Ph phase_2
5
45%
Ph phase_3
4
36%
Ph phase_1
2
18%

Phase Distribution

2

Early Stage

5

Mid Stage

4

Late Stage

Phase Distribution11 total trials
Phase 1Safety & dosage
2(18.2%)
Phase 2Efficacy & side effects
5(45.5%)
Phase 3Large-scale testing
4(36.4%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

83.3%

5 of 6 finished

Non-Completion Rate

16.7%

1 ended early

Currently Active

4

trials recruiting

Total Trials

11

all time

Status Distribution
Active(5)
Completed(5)
Terminated(1)

Detailed Status

Completed5
Recruiting4
Terminated1
Enrolling by invitation1

Development Timeline

Analytics

Development Status

Total Trials
11
Active
4
Success Rate
83.3%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (18.2%)
Phase 25 (45.5%)
Phase 34 (36.4%)

Trials by Status

terminated19%
completed545%
enrolling_by_invitation19%
recruiting436%

Recent Activity

4 active trials
Showing 5 of 11
recruitingphase_2

HEALEY ALS Platform Trial - Master Protocol

NCT04297683
enrolling_by_invitationphase_3

An Open-label Extension Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis

NCT06435312
recruitingphase_2

A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis

NCT06055959
completedphase_3

A Study to Evaluate the Safe and Effective Use of a Zilucoplan Auto-injector by Study Participants With Generalized Myasthenia Gravis

NCT06471361
recruitingphase_1

A Study to Assess Zilucoplan Concentration in Breast Milk of Healthy Lactating Women

NCT06961747
View all 11 trials

Clinical Trials (11)

Showing 11 of 11 trials
NCT04297683Phase 2

HEALEY ALS Platform Trial - Master Protocol

Recruiting
NCT06435312Phase 3

An Open-label Extension Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis

Enrolling By Invitation
NCT06055959Phase 2

A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis

Recruiting
NCT06471361Phase 3

A Study to Evaluate the Safe and Effective Use of a Zilucoplan Auto-injector by Study Participants With Generalized Myasthenia Gravis

Completed
NCT06961747Phase 1

A Study to Assess Zilucoplan Concentration in Breast Milk of Healthy Lactating Women

Recruiting
NCT07215949Phase 3

Zilucoplan for Severe gMG Exacerbations

Recruiting
NCT06511076Phase 1

A Study to Evaluate Zilucoplan Injected Subcutaneously Either by a Prefilled Syringe or an Auto-injector in Healthy Adult Participants

Completed
NCT04382755Phase 2

Zilucoplan® in Improving Oxygenation, Short-, Longterm Outcome of COVID19 Patients With Acute Hypoxic Respiratory Failure

Completed
NCT04436497Phase 2

HEALEY ALS Platform Trial - Regimen A Zilucoplan

Completed
NCT04025632Phase 2

Safety and Efficacy Study of Zilucoplan in Subjects With Immune-Mediated Necrotizing Myopathy

Terminated
NCT04590586Phase 3

Study of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalized Patients

Completed

All 11 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
11